Emergent Biosolutions (EBS) AI Stock Analysis

• Market Cap: $435.34M
• Dividend Yield: N/A
• Average Volume (3M): 1.25M
• Price to Earnings (P/E): 3.3
• Beta (1Y): 3.25
• Revenue Growth: -22.74%
• EPS Growth: N/A
• Country: US
• Employees: 900
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.16
• Shares Outstanding: 53,351,097
• 10 Day Avg. Volume: 1,816,229
• 30 Day Avg. Volume: 1,247,693
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.72
• Enterprise Value/Revenue: 0.78
• Enterprise Value/Gross Profit: 2.47
• Enterprise Value/Ebitda: 7.06
• 1Y Price Target: $12.00
• Price Target Upside: 34.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 65 Neutral
• Price Target: $9.00 ▲(1.01% Upside)

Emergent Biosolutions shows potential with strong technical indicators and an attractive valuation. The positive earnings call and strategic corporate events further support the stock's outlook. However, financial performance challenges and legal uncertainties temper the overall score.

Positive Factors

Financial Performance

Revenues from smallpox MCM products increased $22.7M, or 127% vs. the year-ago period, demonstrating strong growth in this segment.

New Contracts

Emergent recently announced a $65M multi-year contract with Ontario Ministry of Health for NARCAN Nasal Spray, boosting its revenue prospects.

Product Expansion

The expansion of Emergent's NARCANDirect online distribution network to include KLOXXADO Nasal Spray 8mg increases access to opioid overdose response products.

Negative Factors

Market Challenges

Provisional data from the CDC showed an increase in overdose deaths by roughly 1,400 in a 12-month period, highlighting the persistent nature of the opioid crisis.

Revenue Miss

Emergent recorded $140.9M in total top-line revenue, which missed the forecast of $192.1M, indicating challenges in meeting revenue expectations.

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions (EBS) is a global life sciences company focused on providing specialized products and services to address public health needs, particularly in the areas of biodefense, infectious disease, and healthcare. The company operates through two primary segments: Biodefense and Commercial, offering a range of products including vaccines, therapeutics, and diagnostics. EBS is known for its expertise in developing and manufacturing biologics and pharmaceuticals that protect against biological threats and diseases.

How the Company Makes Money

Emergent BioSolutions generates revenue through multiple streams, primarily from the sale of its vaccines and therapeutics in the Biodefense segment, which includes products like anthrax vaccines and botulinum antitoxin. The company also earns revenue from its Commercial segment, which focuses on providing contract development and manufacturing services for various pharmaceutical clients. Significant partnerships with government agencies, such as the U.S. Department of Health and Human Services, along with collaborations with private sector entities, contribute to a steady flow of contracts and funding, particularly for public health preparedness initiatives. Additionally, EBS benefits from licensing agreements and the commercialization of its proprietary products, which further bolster its earnings.

Emergent Biosolutions Financial Statement Overview

Summary

Emergent BioSolutions is facing financial challenges with declining revenue and profitability, negative net income, and shrinking margins. The balance sheet shows moderate leverage but declining equity, while cash flow is volatile despite some recovery.

Income Statement

Emergent Biosolutions has experienced a decline in revenue from 2021 to TTM 2025, coupled with negative net income over the past few periods, indicating profitability issues. The gross profit margin for TTM 2025 is approximately 31.6%, showing a decrease compared to historical figures. The company also faces challenges with negative EBIT and EBITDA margins, signaling operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio for TTM 2025 stands at approximately 1.20, indicating a moderate level of leverage. While the equity ratio is around 38.8%, showing a reasonable balance between equity and assets, the declining stockholders' equity over the years raises concerns about financial stability. The negative ROE underscores ongoing profitability challenges.

Cash Flow

Emergent Biosolutions shows a positive trend in operating cash flow for TTM 2025, with an operating cash flow to net income ratio of approximately -0.84, reflecting cash flow generation despite losses. The free cash flow has improved compared to previous years, suggesting some recovery in cash management. However, the significant fluctuations in cash flow metrics highlight potential volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	960.00M	1.01B	1.05B	1.12B	1.79B	1.56B
Gross Profit	303.40M	305.20M	343.90M	427.20M	1.04B	1.03B
EBITDA	106.30M	36.90M	-505.30M	-32.90M	458.20M	549.00M
Net Income	-131.60M	-190.60M	-760.50M	-223.80M	219.50M	305.80M
Balance Sheet
Total Assets	1.43B	1.39B	1.82B	3.17B	2.96B	2.88B
Cash, Cash Equivalents and Short-Term Investments	149.10M	99.50M	111.70M	642.60M	576.10M	621.30M
Total Debt	665.70M	663.70M	860.20M	1.41B	841.00M	874.80M
Total Liabilities	873.40M	906.90M	1.17B	1.78B	1.34B	1.44B
Stockholders Equity	552.70M	482.80M	649.30M	1.38B	1.62B	1.45B
Cash Flow
Free Cash Flow	94.40M	35.80M	-257.90M	-149.90M	96.10M	395.00M
Operating Cash Flow	110.10M	58.70M	-206.30M	-34.10M	321.10M	536.00M
Investing Cash Flow	195.50M	125.20M	212.30M	-381.30M	-225.00M	-151.00M
Financing Cash Flow	-231.10M	-190.00M	-535.70M	481.20M	-141.00M	69.50M

Emergent Biosolutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Positive. The current price of 8.91 is above the 20-day moving average (MA) of 7.02, above the 50-day MA of 6.80, and above the 200-day MA of 7.52, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 67.74 is Neutral, neither overbought nor oversold. The STOCH value of 79.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EBS.

Emergent Biosolutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	82 Outperform	$665.94M	8.10	43.61%	10.13%	3.86%	-2.60%
ANIP	75 Outperform	$1.84B	―	-2.82%	―	38.68%	-160.14%
EBS	65 Neutral	$435.34M	3.33	30.24%	―	-22.74%	―
DVAX	52 Neutral	$1.23B	64.45	-9.28%	―	26.66%	-419.55%
LFCR	50 Neutral	$270.09M	―	-76.41%	―	0.47%	-430.88%
Sector *	47 Neutral	C$212.69M	-2.68	-24.76%	3.10%	19.76%	0.48%
AQST	44 Neutral	$383.41M	―	77.48%	―	-24.38%	-94.72%

Emergent Biosolutions Corporate Events

Emergent BioSolutions Surpasses Q2 Revenue Expectations

Emergent BioSolutions reported its financial results for the second quarter of 2025, with total revenues of $140.9 million, surpassing guidance by $21 million. Despite a net loss of $12 million, the company showed significant improvements in profitability and margins compared to the previous year. The company raised its full-year profitability guidance and secured several government contracts, reinforcing its position in the medical countermeasures market.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Secures $62.4M ASPR Contract Modification

On June 23, 2025, Emergent BioSolutions announced a $62.4 million contract modification with the Administration for Strategic Preparedness and Response (ASPR) for the supply of BAT®, a botulism antitoxin. This contract modification underscores the U.S. government’s commitment to stockpiling medical countermeasures and highlights Emergent’s role in strengthening global emergency preparedness and public health protection.

The most recent analyst rating on (EBS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent Biosolutions Settlement Receives Preliminary Approval

On May 9, 2025, the United States District Court for the District of Maryland granted preliminary approval for a proposed settlement of shareholder derivative actions against Emergent BioSolutions Inc. The settlement, which includes no admission of fault by the defendants, addresses allegations of fiduciary breaches related to the company’s Bayview facility and its role in manufacturing COVID-19 vaccines. The court has scheduled a hearing for August 6, 2025, to determine final approval. The allegations claimed that Emergent’s management failed to ensure regulatory compliance, leading to significant financial losses and legal challenges.

The most recent analyst rating on (EBS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.